BeOne Medicines (BEIGF) Finished Goods (2017 - 2026)

BeOne Medicines (BEIGF) has reported Finished Goods for 5 consecutive years, with $351.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Finished Goods changed N/A year-over-year to $351.0 million in Q2 2026; TTM through Jun 2026 was $351.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $249.4 million, down 5.65% from the prior year.
• Finished Goods was $351.0 million for Q2 2026 at BeOne Medicines, up from $298.2 million in the prior quarter.
• Over five years, Finished Goods peaked at $351.0 million in Q2 2026 and troughed at $249.4 million in Q4 2025.
• A 3-year average of $290.7 million and a median of $281.2 million in 2024 frame the typical range for Finished Goods.
• The widest YoY moves for Finished Goods: up 5.65% in 2025, down 5.65% in 2025.
• Over 3 years, Finished Goods stood at $264.3 million in 2024, then decreased by 5.65% to $249.4 million in 2025, then soared by 40.77% to $351.0 million in 2026.
• The last three Finished Goods figures came in at $351.0 million (Q2 2026), $298.2 million (Q1 2026), and $249.4 million (Q4 2025), per Business Quant data.